Breaking News Instant updates and real-time market news.

JAZZ

Jazz Pharmaceuticals

$137.74

-4.085 (-2.88%)

, ABBV

AbbVie

$71.14

-0.52 (-0.73%)

12:25
07/11/19
07/11
12:25
07/11/19
12:25

Piper Jaffray health/pharma analysts to hold an analyst/industry conference call

***PLEASE NOTE NEW TIME of 2 pm***Analysts, along with a KOL expert in Graft vs. Host disease (GvHD), discuss Incyte's GvHD candidates, Ruxolitinib and Itacitinib, which are in late-stage development for steroid-refractory and steroid-naive GvHD on an Analyst/Industry conference call to be held on July 11 at 2 pm.

JAZZ

Jazz Pharmaceuticals

$137.74

-4.085 (-2.88%)

ABBV

AbbVie

$71.14

-0.52 (-0.73%)

NVS

Novartis

$90.36

-1.035 (-1.13%)

INCY

Incyte

$81.91

-1.865 (-2.23%)

  • 11

    Jul

  • 22

    Jul

  • 23

    Jul

  • 26

    Jul

  • 30

    Jul

  • 20

    Aug

  • 09

    Sep

  • 16

    Sep

  • 25

    Sep

JAZZ Jazz Pharmaceuticals
$137.74

-4.085 (-2.88%)

07/03/19
RBCM
07/03/19
NO CHANGE
Target $184
RBCM
Outperform
RBC Capital raises peak potential on Jazz Pharmaceuticals' Sunosi after update
RBC Capital analyst Randall Stanicky kept his Outperform rating and $184 price target on Jazz Pharmaceuticals after his discussions with the company detailing its launch plans and commercial landscape for Sunosi which received a Schedule IV designation last month. The analyst notes that while only a limited contribution is expected from the program this year, the company forecast a "more bullish peak outlook than expected" at over $500M in the US.
06/17/19
WELS
06/17/19
NO CHANGE
WELS
Jazz Schedule IV medicine designation a positive outcome, says Wells Fargo
Jazz Pharmaceuticals this morning announced that the U.S. Drug Enforcement Agency has given Sunosi, formerly known as JZP110, a Schedule IV medicine designation, Wells Fargo analyst David Maris tells investors in a research note. The analyst, who points out Provigil is also a Schedule IV drug, believes this outcome is a positive for Jazz and Sunosi. Maris models Sunosi sales of $12M in 2019 and approximately $180M in sales by 2021. He keeps an Outperform rating on shares of Jazz Pharmaceuticals.
07/03/19
LEHM
07/03/19
NO CHANGE
Target $164
LEHM
Overweight
Jazz launch update suggests upside to estimates, says Barclays
Barclays analyst Balaji Prasad says last night's Sunosi launch update from Jazz Pharmaceuticals suggests upside to his estimates. Management guided to $500M in U.S. sales by 2025, suggesting potential upside to the analyst's $300M 2025 U.S. estimate. Prasad adds that while the stock has increased ~20% in the last month, he remains confident in the opportunity and further ~15% upside implied in his price target of $164. The analyst keeps an Overweight rating on Jazz Pharmaceuticals.
07/03/19
MZHO
07/03/19
NO CHANGE
Target $148
MZHO
Neutral
Mizuho more cautious on Jazz's Sunosi after last night's update
Mizuho analyst Irina Koffler says Jazz Pharmaceuticals last night provided a commercial update on Sunosi ahead of its July 8 launch with lower pricing and higher discounting than she previously modeled. The company views its market opportunity as consisting of 165,000 patients in narcolepsy, and another 12M patients with sleep apnea, Koffler tells investors in a research note. Wholesale acquisition cost pricing has been set at $660 per month, below the analyst's $900 per month estimate. Koffler is now more conservative on Sunosi following last night's update and she reiterates a Neutral rating on Jazz shares with a $148 price target.
ABBV AbbVie
$71.14

-0.52 (-0.73%)

06/26/19
06/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConocoPhillips (COP) upgraded to Buy from Neutral at Mizuho with analyst Paul Sankey saying he sees the company being among the best-positioned for the "new E&P model" after having taken major steps to improve unit cash margins via divestitures and liquids-led unconventional growth while reducing fixed cost burdens by undertaking major debt reduction and share buybacks. 2. Micron (MU) upgraded to Buy from Hold at Needham with analyst Rajvindra Gill saying that with an improved DRAM outlook for the second half of 2019, significant CapEx cuts coming in fiscal 2020, and a stabilizing book value per share of $31.89, he believes believe there is limited downside risk over the next 6-12 months. 3. AbbVie (ABBV) upgraded to Outperform from Market Perform at SVB Leerink with analyst Geoffrey Porges citing the "surprise" Allergan (AGN) acquisition announcement, and the stock's 16%-plus selloff intraday. 4. Upwork (UPWK) upgraded to Buy from Hold at Jefferies with analyst Brent Thill citing the stock's 17% year-to-date decline, which he believes has improved the risk/reward balance for the stock. 5. Western Digital (WDC) upgraded to Buy from Hold at Craig-Hallum with analyst Christian Schwab citing Micron's (MU) positive commentary and announced steps targeting supply growth discipline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/03/19
RHCO
07/03/19
NO CHANGE
Target $185
RHCO
Buy
Allergan price target raised to $185 from $170 at SunTrust
SunTrust analyst Gregg Gilbert raised his price target on Allergan (AGN) to $185 and kept his Buy rating to reflect its acquisition by Abbvie (ABBV) at that price, with the deal expected to close early next year. The analyst notes that "meaningful upside" for Allergan holders is possible if Abbvie were to experience multiple expansion before the deal closes, given that the latter trades at a significant price to earnings discount relative to its U.S. major pharma peers.
07/10/19
SBSH
07/10/19
NO CHANGE
SBSH
Neutral
AbbVie risk from Enbrel biosimilars likely manageable, says Citi
Citi analyst Andrew Baum says his analysis suggests that the negative financial impact on Humira from potential U.S. launches of Enbrel biosimilars is likely more limited for AbbVie than envisaged. The likely negative impact of any potential launch on AbbVie's discounted cash flow is at the lower end of the 2%-12% range, Baum tells investors in a research note. He believes the risk is manageable for AbbVie and keeps a Neutral rating on the shares.
06/27/19
WOLF
06/27/19
UPGRADE
WOLF
Peer Perform
AbbVie upgraded to Peer Perform from Underperform at Wolfe Research
Wolfe Research analyst Tim Anderson upgraded AbbVie (ABBV) to Peer Perform from Underperform following the pullback in shares that followed the company's announcement of an agreement to acquire Allergan (AGN). However, Anderson lowered his price target on AbbVie shares to $74 from $84.
NVS Novartis
$90.36

-1.035 (-1.13%)

07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/14/19
PIPR
06/14/19
NO CHANGE
Target $120
PIPR
Neutral
Price tag of Bluebird's Zynteglo 'hard to justify,' says Piper Jaffray
The $1.8M price tag of Bluebird Bio's Zynteglo is "hard to justify" given the $2.1M comp of Novartis' (NVS) Zolgensma, which treats children with a certain outcome of death, as opposed to a population where the majority of patients are adequately maintained on transfusions, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. In Zynteglo clinical trials, only 60 beta-thal patients have been enrolled and 16 sickle cell patients have ever been infused, the analyst points out. Yet, says Van Buren, the Street is modeling that Bluebird transplants thousands of patients with Zynteglo. He continues to believe uptake of the gene therapy will be challenging and keeps a Neutral rating on Bluebird Bio with a $120 price target.
06/18/19
06/18/19
DOWNGRADE

Hold
Regeneron downgraded to Hold at Argus on mounting threats to Eylea
As previously reported, Argus analyst Jasper Hellweg downgraded Regeneron (REGN) to Hold from Buy, saying that while the company has a "strong pipeline" with new recent indications for multiple products, its primary revenue driver Eylea is facing several competitive threats. The analyst notes that Novartis (NVS) could launch a biologic designed to treat Eylea's key indication of wet age-related macular degeneration by the end of Q2 and also notes that the drug's patents are set to expire in 2022 in China and Japan, 2023 in the U.S., and 2024 in Europe. Hellweg adds that he will return his Regeneron rating to Buy if the company demonstrates that it can offset the impact of reduced Eylea sales, which accounted for over 75% of total revenue in Q1.
06/28/19
PIPR
06/28/19
DOWNGRADE
Target $250
PIPR
Neutral
Biogen downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Biogen (BIIB) to Neutral from Overweight and lowered his price target for the shares to $250 from $280. The stock closed yesterday up $1.70 to $239.77. Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term," Raymond tells investors in a research note. For the first time in a long time, Tecfidera market share is projected to contract over the next six months, primarily at the hands of Novartis' (NVS) new entrant Mayzent, explains the analyst. Further, Raymond notes that while prior surveys have indicated a plateauing of Roche's (RHHBY) Ocrevus with Biogen's Tysabri "hanging in there," the most recent indications are for an accelerating Ocrevus with Tysabri the "clear loser." The analyst lowered his estimates for both Tecfidera and Tysabri and downgraded Biogen.
INCY Incyte
$81.91

-1.865 (-2.23%)

05/20/19
FBCO
05/20/19
INITIATION
Target $75
FBCO
Neutral
Incyte initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Incyte with a Neutral rating and $75 price target. The analyst wants to see more clinical evidence and trial execution in the company's its pipeline following last year's failure of epacadostat before coming more positive on the stock.
06/18/19
RHCO
06/18/19
DOWNGRADE
Target $48
RHCO
Hold
Array BioPharma downgraded to Hold from Buy at SunTrust
SunTrust analyst Peter Lawson downgraded Array BioPharma (ARRY) to Hold but raised his price target to $48 from $32 after the company announced that it is being acquired by Pfizer (PFE) at that price. The analyst notes that the 79% premium to the company's last closing price looks like a "fair valuation" based on his analysis of past comps and his M&A valuation model. Lawson adds that the the deal is "encouraging" within the biotech space with positive implications for other potential acquisition targets such as Agios Pharmaceuticals (AGIO) and Mirati herapeutics (MRTX) along with companies with strong chemistry such Incyte Corporation (INCY) and Exelixis (EXEL).
06/17/19
PIPR
06/17/19
NO CHANGE
PIPR
Overweight
Incyte congress presentations reinforce Piper's enthusiam for ruxolitinib cream
Piper Jaffray analyst Tyler Van Buren said Incyte reported positive updates for the topical ruxolitinib programs in vitiligo and atopic dermatitis at the World Congress of Dermatology, which he said "further reinforce" the enthusiasm he has about the product candidate. In the data presented at the meeting, ruxolitinib demonstrated "impressive" activity in vitiligo and "solid efficacy" in atopic dermatitis out to 12 weeks, said Van Buren, who thinks the drug could generate over $1B in global sales by the late 2020s for its combined eventual indications. He keeps an Overweight rating on Incyte shares.
05/21/19
05/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Uber (UBER) initiated with an Equal Weight at Consumer Edge and a Neutral at Susquehanna. 2. Incyte (INCY) initiated with a Neutral at Credit Suisse. 3. Hillenbrand (HI) initiated with a Neutral at DA Davidson. 4. Target Hospitality (TH) initiated with a Buy at Deutsche Bank. 5. Jack in the Box (JACK) reinstated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

AN

AutoNation

$42.01

-0.045 (-0.11%)

18:17
07/22/19
07/22
18:17
07/22/19
18:17
Earnings
AutoNation reports Q2 cont ops EPS $1.12, consensus $1.06 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 13

    Nov

CR

Crane

$86.50

0.99 (1.16%)

18:15
07/22/19
07/22
18:15
07/22/19
18:15
Earnings
Crane backs FY19 adjusted EPS view of $6.25-$6.45, consensus $6.41 »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 09

    Sep

  • 09

    Sep

CR

Crane

$86.50

0.99 (1.16%)

18:14
07/22/19
07/22
18:14
07/22/19
18:14
Earnings
Crane Co. reports Q2 EPS ex-items $1.58, consensus $1.56 »

Reports Q2 revenue $842M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 09

    Sep

  • 09

    Sep

AN

AutoNation

$42.01

-0.045 (-0.11%)

, GOOG

Alphabet

$1,138.09

8.09 (0.72%)

18:11
07/22/19
07/22
18:11
07/22/19
18:11
Hot Stocks
AutoNation names Cheryl Miller CEO »

AutoNation (AN) announced…

AN

AutoNation

$42.01

-0.045 (-0.11%)

GOOG

Alphabet

$1,138.09

8.09 (0.72%)

GOOGL

Alphabet Class A

$1,139.52

7.85 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Jul

  • 25

    Jul

  • 03

    Aug

  • 08

    Aug

  • 27

    Oct

  • 13

    Nov

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

18:04
07/22/19
07/22
18:04
07/22/19
18:04
Hot Stocks
Steel Dynamics reports Q2 operating income $295M, down 6% from Q1 »

Q2 average external…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

FBMS

First Bancshares

$29.74

-0.105 (-0.35%)

18:03
07/22/19
07/22
18:03
07/22/19
18:03
Hot Stocks
First Bancshares announces agreement to acquires First Florida Bancorp »

The First Bancshares,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

18:03
07/22/19
07/22
18:03
07/22/19
18:03
Hot Stocks
Steel Dynamics CEO sees 'modest growth' for steel consumption in second half »

CEO Mark Millett says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

18:01
07/22/19
07/22
18:01
07/22/19
18:01
Earnings
Steel Dynamics reports Q2 EPS 87c, consensus 89c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

FDEF

First Defiance Financial

$27.22

-0.04 (-0.15%)

17:58
07/22/19
07/22
17:58
07/22/19
17:58
Earnings
First Defiance Financial reports Q2 EPS 61c, consensus 58c »

"Solid loan growth,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

QCOM

Qualcomm

$75.93

0.9 (1.20%)

, INTC

Intel

$51.36

1.1 (2.19%)

17:58
07/22/19
07/22
17:58
07/22/19
17:58
Hot Stocks
Qualcomm falls after news Apple may buy Intel smartphone-modem chip business »

Shares of Qualcomm (QCOM)…

QCOM

Qualcomm

$75.93

0.9 (1.20%)

INTC

Intel

$51.36

1.1 (2.19%)

AAPL

Apple

$207.21

4.59 (2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 03

    Aug

SPY

SPDR S&P 500 ETF Trust

$297.82

0.65 (0.22%)

, SPX

S&P 500

$0.00

(0.00%)

17:51
07/22/19
07/22
17:51
07/22/19
17:51
General News
Trump tweets budget deal reached with no poison pills »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$297.82

0.65 (0.22%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAFD

Washington Federal

$34.85

-0.12 (-0.34%)

17:46
07/22/19
07/22
17:46
07/22/19
17:46
Hot Stocks
Washington Federal raises dividend 5% »

Washington Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBMS

First Bancshares

$29.74

-0.105 (-0.35%)

17:46
07/22/19
07/22
17:46
07/22/19
17:46
Earnings
First Bancshares reports Q2 EPS ex-items 79c, consensus 69c »

M. Ray "Hoppy"…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

NTDOY

Nintendo

$0.00

(0.00%)

17:43
07/22/19
07/22
17:43
07/22/19
17:43
Periodicals
Law firm sues Nintendo over Joy-Con drift, Polygon reports »

Chimicles Schwartz Kriner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OEC

Orion Engineered

$18.41

0.05 (0.27%)

17:33
07/22/19
07/22
17:33
07/22/19
17:33
Hot Stocks
Orion Engineered announces price increases »

Orion Engineered Carbons…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 06

    Aug

HMST

HomeStreet

$27.76

-0.03 (-0.11%)

17:31
07/22/19
07/22
17:31
07/22/19
17:31
Earnings
HomeStreet reports Q2 core EPS 13c, consensus 52c »

"The second quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

GLD

SPDR Gold Shares

$134.46

(0.00%)

17:31
07/22/19
07/22
17:31
07/22/19
17:31
Hot Stocks
SPDR Gold Shares holdings rise to 825.18MT from 820.49MT »

This is the 4th…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARX

RA Pharmaceuticals

$36.01

2.42 (7.20%)

17:29
07/22/19
07/22
17:29
07/22/19
17:29
Syndicate
RA Pharmaceuticals files to sell $100M of common stock »

Jefferies, BMO Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHE

Benchmark Electronics

$25.05

0.22 (0.89%)

17:29
07/22/19
07/22
17:29
07/22/19
17:29
Hot Stocks
Benchmark Electronics appoints Rob Crawford Chief Revenue Officer »

Benchmark Electronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

AAPL

Apple

$207.21

4.59 (2.27%)

, INTC

Intel

$51.36

1.1 (2.19%)

17:28
07/22/19
07/22
17:28
07/22/19
17:28
Periodicals
Apple may pay $1B or more for Intel patents, staff in chip unit deal, WSJ says »

Apple (AAPL) is in…

AAPL

Apple

$207.21

4.59 (2.27%)

INTC

Intel

$51.36

1.1 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 03

    Aug

ATVI

Activision Blizzard

$45.57

0.43 (0.95%)

17:26
07/22/19
07/22
17:26
07/22/19
17:26
Hot Stocks
Blizzard co-founder Frank Pearce departing after 28 years »

One of the founders of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 05

    Sep

NBSE

NeuBase Therapeutics

$3.55

-0.58 (-14.04%)

17:25
07/22/19
07/22
17:25
07/22/19
17:25
Hot Stocks
Carnegie Mellon reports 5.5% passive stake in NeuBase Therapeutics »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CADE

Cadence Bancorp

$15.86

-3.75 (-19.12%)

17:23
07/22/19
07/22
17:23
07/22/19
17:23
Downgrade
Cadence Bancorp rating change  »

Cadence Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 06

    Aug

  • 26

    Aug

  • 23

    Sep

CAL

Caleres

$18.27

0.27 (1.50%)

17:22
07/22/19
07/22
17:22
07/22/19
17:22
Hot Stocks
Caleres, Veronica Beard announce exclusive footwear partnership »

Caleres and Veronica…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

AAPL

Apple

$207.21

4.59 (2.27%)

, INTC

Intel

$51.36

1.1 (2.19%)

17:22
07/22/19
07/22
17:22
07/22/19
17:22
Periodicals
Breaking Periodicals news story on Apple, Intel »

Apple in advanced talks…

AAPL

Apple

$207.21

4.59 (2.27%)

INTC

Intel

$51.36

1.1 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 03

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.